Shandong Xinhua Pharmaceutical Co., Ltd. (000756.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	8.5B	8.8B	8.5B	8.1B	7.5B
Cost of Revenue	7.0B	7.1B	6.4B	5.7B	5.5B
Gross Profit	1.5B	1.6B	2.0B	2.4B	2.0B
Operating Expenses
R&D Expense	364.8M	381.6M	413.2M	419.2M	345.7M
SG&A Expense	178.9M	—	—	—	—
General & Admin Expense	446.0M	457.7M	437.1M	513.8M	453.5M
Selling & Marketing Expense	336.2M	341.1M	584.7M	780.2M	658.3M
Other Expenses	23.9M	—	—	—	—
Total Operating Expenses	1.3B	1.3B	1.5B	1.8B	1.6B
Cost and Expenses	8.2B	8.4B	7.9B	7.5B	7.0B
Operating Income (EBIT)	276.2M	364.0M	534.4M	534.6M	476.7M
Non-Operating
Interest Income	8.4M	—	—	—	—
Interest Expense	8.8M	—	—	—	—
Net Interest Income	(332.6K)	—	—	—	—
Other Non-Op Income/Expense	(11.1M)	—	—	—	—
Non-Operating Income (excl Interest)	2.9M	—	—	—	—
EBT (Pre-Tax Income)	260.1M	358.9M	533.7M	532.7M	471.8M
Income Tax Expense	37.3M	52.6M	46.9M	26.6M	45.7M
Bottom Line
Net Income	215.0M	289.9M	470.0M	496.5M	411.1M
Earnings from Cont. Ops	222.8M	306.3M	486.7M	506.1M	426.1M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	215.0M	289.9M	470.0M	496.5M	411.1M
Per Share
Basic EPS	CN¥0.31	CN¥0.42	CN¥0.69	CN¥0.74	CN¥0.62
Diluted EPS	CN¥0.32	CN¥0.42	CN¥0.68	CN¥0.72	CN¥0.61
Revenue Per Share	CN¥12.15	CN¥12.68	CN¥12.43	CN¥12.07	CN¥11.32
Shares
Basic Shares Outstanding	696.7M	690.2M	681.2M	671.0M	663.0M
Diluted Shares Outstanding	696.7M	690.2M	681.2M	671.0M	663.0M
Profitability Metrics
EBITDA	209.3M	954.4M	1.1B	1.1B	966.1M
D&A	152.1M	590.5M	543.6M	517.4M	489.4M
EBIT	57.5M	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026